Targets › KRAS
107 programs from 74 companies in 279 trials: 145 Phase 1, 88 Phase 2, 45 Phase 3, 1 Phase 4; Oncology, Other, Immunology; next expected readout Nov 2026.
Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. (UniProt, P01116)
Open in Phaseline: the race on KRAS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Aarhus University Hospital | Enstilar Topical combination (calcipotriol + betamethasone dipropionate) | KRAS | Phase 4 | Psoriasis Vulgaris | Dec 2026 |
| Bristol-Myers Squibb | Adagrasib GTPase KRas inhibitor | KRAS | Phase 3 | Metastatic Non Small Cell Lung Cancer; Advanced Colorectal Cancer; Carcinoma, Non-Small-Cell Lung; Advanced Cancer … | Nov 2026 |
| Allist Pharmaceuticals | JAB-21822 KRAS G12C inhibitor | KRAS | Phase 3 | Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12C; Advanced Colorectal Cancer; NSCLC … | Dec 2026 |
| Amgen | Sotorasib GTPase KRas inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer (NSCLC); Metastatic Colorectal Cancer; Advanced Solid Tumors; Lung Adenocarcinoma … | Dec 2026 |
| Revolution Medicines | RMC-6236 RAS(ON) inhibitor - KRAS G12C inhibitor | KRAS | Phase 3 | Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal Cancer | Dec 2026 |
| Incyte | INCB161734 KRAS G12D inhibitor | KRAS | Phase 3 | Solid Tumors; Healthy Participants | Jan 2027 |
| Novartis | JDQ443 KRAS G12C inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer; Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation; KRAS G12C Mutant Solid Tumors; NSCLC | Jan 2027 |
| Jiangsu HengRui Medicine | HRS-4642 KRAS G12D inhibitor | KRAS | Phase 3 | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting; Advanced KRAS G12D Mutant Solid Tumors; Advanced Solid Tumors; Metastatic Pancreatic Carcinoma … | Mar 2027 |
| Eli Lilly | Olomorasib (LY3537982) KRAS G12C inhibitor | KRAS | Phase 3 | Carcinoma, Non-Small-Cell Lung; Healthy Volunteers | Apr 2027 |
| Astellas | Setidegrasib (ASP3082) KRAS G12D inhibitor | KRAS | Phase 3 | Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Healthy Volunteer | May 2027 |
| Genfleet Therapeutics (Shanghai) | Cetuximab (GFH375) KRAS G12D inhibitor | KRAS | Phase 3 | Metastatic Pancreatic Cancer; KRAS G12D Mutation; Pancreatic Cancer; Advanced Solid Tumors Cancer … | Jun 2027 |
| Revolution Medicines | Daraxonrasib KRAS(ON) inhibitor | KRAS | Phase 3 | NSCLC (Non-small Cell Lung Cancer); Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer (NSCLC) … | Dec 2027 |
| Chia Tai Tianqing Pharmaceutical Group | D-1553 Tablet KRAS G12C inhibitor | KRAS | Phase 3 | Non Small Cell Lung Cancer | Dec 2027 |
| InxMed (Shanghai) | D-1553 KRAS G12C inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer; Solid Tumor | Dec 2027 |
| Merck & Co. (MSD) | Calderasib (MK-1084) KRAS G12C inhibitor | KRAS | Phase 3 | Non-small Cell Lung Cancer; Colon Adenocarcinoma; Malignant Neoplasm; Neoplasm Malignant … | Jan 2028 |
| Roche | Divarasib KRAS G12C inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Colorectal Cancer | Nov 2028 |
| Revolution Medicines | Zoldonrasib KRAS(ON) inhibitor | KRAS | Phase 3 | Pancreatic Cancer; NSCLC; Advanced Solid Tumors | Dec 2028 |
| Ranok Therapeutics (Hangzhou) | RNK08954 KRAS G12D inhibitor | KRAS | Phase 2 | KRAS G12D Mutations | Nov 2026 |
| Shandong Suncadia Medicine | HRS-7058 KRAS G12C selective inhibitor | KRAS | Phase 2 | Advanced Malignant Tumour; Solid Tumors; Pancreatic Cancer | Dec 2026 |
| Guangzhou JOYO Pharma | JYP0015 Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS | KRAS, NRAS, HRAS | Phase 2 | Solid Tumor | Dec 2026 |
| Georgetown University | KRAS vaccine KRAS-directed cancer vaccine (Targovax TG01 with Stimulon QS-21 adjuvant) | KRAS | Phase 2 | Pancreatic Ductal Adenocarcinoma | Jun 2027 |
| Verastem | VS-7375 KRAS G12D inhibitor | KRAS | Phase 2 | Colorectal Cancer; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Ductal Adenocarcinoma | Jun 2027 |
| Abbisko Therapeutics | ABSK043 KRAS inhibitor | KRAS | Phase 2 | Non-Small Cell Lung Cancer With EGFR Mutation; Non-Small Cell Lung Cancer; Neoplasms | Jul 2027 |
| Gustave Roussy, Cancer Campus, Grand Paris | ASP3082 KRAS G12D inhibitor | KRAS | Phase 2 | Metastatic/Locally Advanced Non-Small-Cell Lung Cancer | Sep 2027 |
| Guangdong Association of Clinical Trials | IBI351 KRAS G12C inhibitor | KRAS | Phase 2 | Lung Cancer (Non-Small Cell) | Sep 2027 |
| Guangdong Provincial People's Hospital | Garsorasib KRAS G12C inhibitor | KRAS | Phase 2 | Lung Cancer (NSCLC) | Dec 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Glecirasib KRAS G12C inhibitor | KRAS | Phase 2 | NSCLC | Jan 2028 |
| Bristol-Myers Squibb | Daraxonrasib (RMC-6236) KRAS inhibitor | KRAS | Phase 2 | Solid Tumors | Aug 2028 |
| Jeeyun Lee | Rilvegostomig KRAS G12D inhibitor | KRAS | Phase 2 | Stomach Neoplasms | Oct 2028 |
| Zhejiang University | fulzerasib KRAS G12C inhibitor | KRAS | Phase 2 | Colorectal Cancer | Dec 2028 |
| Elicio Therapeutics | ELI-002 7P Lipid-conjugated CpG oligonucleotide (Amph-CpG-7909) plus lipid-conjugated peptide-based a | KRAS, NRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer | Nov 2026 |
| Boehringer Ingelheim | BI 1701963 KRAS reactivation inhibitor | KRAS | Phase 1 | Solid Tumors, KRAS Mutation; Solid Tumors, KRAS Mutation; SOS1 | Nov 2026 |
| Boehringer Ingelheim | BI 1823911 KRAS inhibitor | KRAS | Phase 1 | Solid Tumors, KRAS Mutation | Nov 2026 |
| Arvinas | ARV-806 KRAS G12D degrader (targeted protein degradation) | KRAS | Phase 1 | KRAS G12D Mutation | Nov 2026 |
| Sichuan Huiyu Pharmaceutical | HYP-2090PTSA KRAS G12C inhibitor | KRAS | Phase 1 | Safety | Dec 2026 |
| PAQ Therapeutics | PT0253 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumor | Dec 2026 |
| Ranok Therapeutics (Hangzhou) | RNK08954-01 KRAS G12D inhibitor | KRAS | Phase 1 | KRAS G12D Mutation | Dec 2026 |
| HUYABIO International | HBI-2438 KRAS G12C inhibitor | KRAS | Phase 1 | Lung Cancer | Dec 2026 |
| Jacobio Pharmaceuticals | JAB-23E73 Pan-KRAS inhibitor | KRAS | Phase 1 | Advanced Solid Tumor; Advanced Solid Tumors; Metastatic Pancreatic Ductal Adenocarcinoma | Dec 2026 |
| Pharosgen | MPD-1 Doxorubicin prodrug targeting KRAS mutant/PTEN loss advanced cancer | KRAS, PTEN | Phase 1 | Cancer | Dec 2026 |
| Revolution Medicines | RMC-9805 RAS(ON) inhibitor - KRAS inhibitor | KRAS | Phase 1 | Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC; Colorectal Cancer | Dec 2026 |
| Quanta Therapeutics | QTX3544 KRAS G12V inhibitor | KRAS | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| Zhejiang University | NW-301VT T Cell Receptor (TCR)-engineered T cell therapy targeting KRAS G12V mutation with dominant | KRAS | Phase 1 | Tumor | Feb 2027 |
| Kumquat Biosciences | KQB548 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumor Malignancies | Mar 2027 |
| Incyte | INCB186748 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumors | Mar 2027 |
| Sun Yat-sen University | IX001 TCR-T injection TCR-T cell therapy targeting KRAS G12V mutation | KRAS | Phase 1 | Pancreatic Cancer | Mar 2027 |
| Revolution Medicines | RMC-6291 KRAS(ON) inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer, NSCLC | Mar 2027 |
| Quanta Therapeutics | QTX3034 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumors | Apr 2027 |
| Henan Cancer Hospital | RE002 T cell TCR-engineered T cell therapy targeting KRAS G12D mutation | KRAS | Phase 1 | KRAS G12D | Apr 2027 |
| Ting Deng | NW-301D T cell receptor (TCR)-engineered T cell therapy targeting KRAS G12D mutation | KRAS | Phase 1 | Tumor, Solid | Apr 2027 |
| Ting Deng | NW-301V T cell receptor (TCR)-engineered T cell therapy targeting KRAS G12V mutation | KRAS | Phase 1 | Tumor, Solid | Apr 2027 |
| D3 Bio (Wuxi) | D3S-001 KRAS G12C inhibitor | KRAS | Phase 1 | KRAS P.G12C | Apr 2027 |
| M.D. Anderson Cancer Center | Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA KRAS G12D-targeted siRNA delivered via mesenchymal stromal cell-derived exosomes | KRAS | Phase 1 | KRAS NP_004976.2:p.G12D | Apr 2027 |
| Qilu Pharmaceutical | QLC1101 KRAS G12D inhibitor | KRAS | Phase 1 | Non-small Cell Lung Cancer | Apr 2027 |
| Tyligand Pharmaceuticals (Suzhou) | TSN1611 KRAS G12D inhibitor | KRAS | Phase 1 | Malignant Neoplasm | Apr 2027 |
| Oslo University Hospital | TG01/QS-21 KRAS/NRAS mutation-specific peptide vaccine with QS-21 adjuvant | KRAS, NRAS | Phase 1 | Multiple Myeloma | May 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mutant KRAS peptide vaccine KRAS mutant-targeted long peptide vaccine | KRAS | Phase 1 | Colorectal Cancer; High Risk Cancer | Jun 2027 |
| Changhai Hospital | Mutant KRAS G12V-specific TCR transduced autologous T cells TCR-engineered T cells targeting mutant KRAS G12V mutation in HLA-A*11:01 context | KRAS | Phase 1 | Pancreatic Cancer | Jun 2027 |
| TingBo Liang | NW-301D TCR-T cell targeting KRAS G12D mutation | KRAS | Phase 1 | Tumor, Solid | Jun 2027 |
| TingBo Liang | NW-301V TCR-T cell targeting KRAS G12V mutation | KRAS | Phase 1 | Tumor, Solid | Jun 2027 |
| Tango Therapeutics | RMC-9805 RAS(ON) G12D selective covalent inhibitor | KRAS | Phase 1 | PDAC | Jun 2027 |
| Tao Zhang | NW-301D TCR-T cell targeting KRAS G12D mutation | KRAS | Phase 1 | Tumor, Solid | Jun 2027 |
| Tao Zhang | NW-301V TCR-T cell targeting KRAS G12V mutation | KRAS | Phase 1 | Tumor, Solid | Jun 2027 |
| Quanta Therapeutics | QTX3046 KRAS G12D inhibitor | KRAS | Phase 1 | Advanced Solid Tumor | Jul 2027 |
| Innovent Biologics (Suzhou) | IBI351 KRAS G12C inhibitor | KRAS | Phase 1 | Advanced Non-Small Cell Lung Cancer | Jul 2027 |
| Vividion Therapeutics | VVD-159642 RAS-PI3Kα inhibitor | KRAS, PIK3CA | Phase 1 | Advanced Solid Tumors | Aug 2027 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-10203 PI3Kα:RAS breaker | PIK3CA, KRAS, NRAS, HRAS | Phase 1 | Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung Cancer | Aug 2027 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-11818 pan-KRAS inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer | Aug 2027 |
| Frontier Medicines | FMC-376 KRAS G12C inhibitor | KRAS | Phase 1 | Advanced Solid Tumors With KRAS G12C Mutations | Oct 2027 |
| InventisBio | D-1553 KRAS G12C inhibitor | KRAS | Phase 1 | Solid Tumor | Dec 2027 |
| Roche | GDC-6036 KRAS G12C inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer | Dec 2027 |
| Sichuan University | KRAS-mutated mRNA vaccine mRNA vaccine targeting KRAS mutations | KRAS | Phase 1 | Malignant Tumors | Dec 2027 |
| D3 Bio (Wuxi) | D3S-003 KRAS G12D inhibitor | KRAS | Phase 1 | KRAS P.G12D | Jan 2028 |
| Adlai Nortye Biopharma | AN9025 Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R | KRAS, NRAS, HRAS | Phase 1 | Solid Tumors (Phase 1) | Jan 2028 |
| Eli Lilly | LY3962673 KRAS G12D inhibitor | KRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma | Mar 2028 |
| Kestrel Therapeutics, Inc. | KST-6051 KRAS inhibitor | KRAS | Phase 1 | KRAS-mutant Non-small Cell Lung Cancer (NSCLC) | Apr 2028 |
| Amgen | AMG 410 KRAS G12C inhibitor | KRAS | Phase 1 | KRAS Altered Advanced or Metastatic Solid Tumors | Apr 2028 |
| Jiangsu HengRui Medicine | HRS-6093 KRAS G12D inhibitor | KRAS | Phase 1 | Advanced KRAS G12D Mutant Solid Tumors | May 2028 |
| Roche | GDC-7035 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumor | May 2028 |
| Institut de Recherches Internationales Servier | S241656 RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) | BRAF, CRAF, KRAS, NRAS | Phase 1 | Non-small Cell Lung Cancer | Jun 2028 |
| Erasca | ERAS-4001 KRAS inhibitor | KRAS | Phase 1 | Metastatic Solid Tumors | Aug 2028 |
| Genuine Seed Therapeutics (Zhuhai) | GST101 KRAS inhibitor | KRAS | Phase 1 | RAS-mutant Advanced Solid Tumors | Oct 2028 |
| PAQ Therapeutics | PT0511 KRAS inhibitor | KRAS | Phase 1 | Colorectal Cancer | Oct 2028 |
| Ensem Therapeutics | ETX-929 pan-KRAS inhibitor | KRAS | Phase 1 | Metastatic Colorectal Cancer (CRC) | Oct 2028 |
| Astellas | ASP5834 KRAS mutant inhibitor | KRAS | Phase 1 | Solid Tumor | Nov 2028 |
| Corregene Biotechnology | KRAS-specific Autologous TCR-T cell injection (CRTKVA11-N04) KRAS G12V-specific T-cell receptor engineered T-cell therapy | KRAS | Phase 1 | Colorectal | Nov 2028 |
| Johnson & Johnson (Janssen) | Olomorasib KRAS G12C inhibitor | KRAS | Phase 1 | Carcinoma, Non-Small-Cell Lung | Nov 2028 |
| Revolution Medicines | Elironrasib KRAS(ON) inhibitor | KRAS | Phase 1 | Non-Small Cell Lung Cancer (NSCLC); Advanced Solid Tumors | Dec 2028 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | SLP mKRASvax with Poly-ICLC adjuvant Synthetic long peptide vaccine targeting mutant KRAS with Poly-ICLC (TLR3 agonist) adjuvan | KRAS | Phase 1 | Pancreatic Cancer; Colorectal Cancer | Dec 2028 |
| Adlai Nortye Biopharma | AN4035 CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload | CEACAM5, KRAS, NRAS, HRAS | Phase 1 | Solid Tumor (Phase I) | Dec 2028 |
| National Cancer Institute (NCI) | GRT-C903/GRT-R904 Vaccine directed against KRAS mutation antigens | KRAS | Phase 1 | Metastatic Solid Cancers | Feb 2029 |
| Shenzhen Ionova Life Sciences | INV-8989 KRAS G12D inhibitor | KRAS | Phase 1 | Advance Solid Tumors | May 2029 |
| Novartis | Opnurasib KRAS inhibitor | KRAS | Phase 1 | Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer | Jun 2029 |
| National Cancer Institute (NCI) | Anti-KRAS G12V mTCR PBL Murine T-cell receptor recognizing KRAS G12V variant | KRAS | Phase 1 | Pancreatic Cancer | Jun 2029 |
| Bayer | BAY 3771249 KRAS G12D inhibitor | KRAS | Phase 1 | Advanced/Metastatic Colorectal Adenocarcinoma | Jul 2029 |
| Blueprint Medicines | BLU-924 (SAR449336) pan-KRAS inhibitor | KRAS | Phase 1 | Advanced Solid Tumor | Sep 2029 |
| Daiichi Sankyo | Olomorasib KRAS G12C inhibitor | KRAS | Phase 1 | Urothelial Cancer | Sep 2029 |
| Affini-T Therapeutics | AFNT-211 Engineered TCR T-cell recognizing KRAS G12V | KRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma | Dec 2029 |
| Abbisko Therapeutics | ABSK211 KRAS inhibitor | KRAS | Phase 1 | Solid Tumor (Phase I) | Dec 2029 |
| Eli Lilly | LY4066434 Pan-KRAS inhibitor | KRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma | Jan 2030 |
| Anocca AB | ANOC-001 TCR-engineered T cells targeting KRAS G12V mutation presented by specific HLA alleles | KRAS | Phase 1 | PDAC | Apr 2030 |
| Anocca AB | ANOC-002 TCR-engineered T cells targeting KRAS G12V mutation presented by specific HLA alleles | KRAS | Phase 1 | PDAC | Apr 2030 |
| Anocca AB | ANOC-003 TCR-engineered T cells targeting KRAS G12D mutation presented by specific HLA alleles | KRAS | Phase 1 | PDAC | Apr 2030 |
| Memorial Sloan Kettering Cancer Center | MSK-TCR5 T cell receptor (TCR) engineered to recognize RAS G12D mutations | KRAS, HRAS, NRAS | Phase 1 | Solid Tumor | Jun 2030 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-8520 KRAS G12C ON and OFF inhibitor | KRAS | Phase 1 | Non-small Cell Lung Cancer | Apr 2031 |
| Pfizer | PF-07934040 panKRAS inhibitor | KRAS | Phase 1 | Carcinoma, Pancreatic Ductal | – |
| Shanghai YingLi Pharmaceutical | YL-17231 Pan-RAS inhibitor | KRAS, HRAS, NRAS | Phase 1 | Advanced Solid Tumors | – |
Colorectal Cancer (16) Pancreatic Cancer (15) Non-small Cell Lung Cancer (11) Non-Small Cell Lung Cancer (11) Advanced Solid Tumors (11) Metastatic Colorectal Cancer (9) Solid Tumors (7) Solid Tumor (7) Pancreatic Ductal Adenocarcinoma (6) Tumor, Solid (6) Head and Neck Cancer (6) Carcinoma, Non-Small-Cell Lung (5)
mixed (52), small molecule (44), other (6), protein or peptide (3), antibody (2)
Revolution Medicines (6) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (3) Anocca AB (3) Quanta Therapeutics (3) Roche (3) Eli Lilly (3) Bristol-Myers Squibb (2) Zhejiang University (2) Amgen (2) Novartis (2) Astellas (2) National Cancer Institute (NCI) (2) Abbisko Therapeutics (2) Ranok Therapeutics (Hangzhou) (2) Tao Zhang (2) Incyte (2) D3 Bio (Wuxi) (2) Adlai Nortye Biopharma (2) Jiangsu HengRui Medicine (2) Ting Deng (2)
NRAS (9) HRAS (6) PIK3CA (2) PTEN (1) BRAF (1) CRAF (1) CEACAM5 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.